Patents by Inventor Kan Cao

Kan Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD AND AUTOMATIC BRAZING APPARATUS FOR FLAME BRAZING CONTROL IN COPPER-ALUMINUM WELDING
    Publication number: 20240173788
    Abstract: Disclosed is a flame brazing control method for copper-aluminum welding, characterized by using a flame generated from the combustion of natural gas, air and oxygen as the heat source, the molar flow ratio of natural gas, air and oxygen is controlled within a range of 1:10-22:0.3-2.2. Further disclosed is an automatic brazing apparatus for copper-aluminum welding, characterized by using a flame generated from the combustion of natural gas, air and oxygen as the heat source, includes three gas delivery systems for natural gas, air and oxygen, a mixer for mixing the three gas, and integrated flow controllers for the electromagnetic valves and flow valves in the three gas delivery systems.
    Type: Application
    Filed: December 30, 2022
    Publication date: May 30, 2024
    Inventors: Shuiqing WANG, Kan CAO, Qiang LIANG, Kang XU, Xiyun WANG, Yinbin LOU
  • Novel Ingredient in Sunscreen Compositions
    Publication number: 20240099952
    Abstract: A sunscreen composition, containing an effective amount of Methylene Blue and/or a hydrate and or a pharmaceutically-acceptable salt thereof; an effective amount of one or more UVA and/or UVB absorbing compounds, with the proviso that Oxybenzone and Octinoxate are excluded; and an excipient base.
    Type: Application
    Filed: October 16, 2020
    Publication date: March 28, 2024
    Inventors: Kan Cao, Chandamany Arya, Jasmin El Kordi
  • Oligonucleotide analogues targeting human LMNA
    Patent number: 11802283
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 31, 2023
    Assignees: Sarepta Therapeutics, Inc., The United States of America, as rep. by the Secretary, Dept. of Health and Human Services, The Progeria Research Foundation
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA
    Publication number: 20210010001
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 14, 2021
    Applicants: Sarepta Therapeutics, Inc., The Progeria Research Foundation, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, University of Maryland, The Progeria Research Foundation
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • METHODS OF TREATING AGE-RELATED SYMPTOMS IN MAMMALS AND COMPOSITIONS THEREFOR
    Publication number: 20200352954
    Abstract: A method of alleviating age-related symptoms in a mammal, which comprises a step of administering to a mammal in need thereof, an effective amount of a composition containing an effective amount of at least methylene blue.
    Type: Application
    Filed: March 30, 2020
    Publication date: November 12, 2020
    Inventor: Kan CAO
  • Oligonucleotide analogues targeting human LMNA
    Patent number: 10822608
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 3, 2020
    Assignees: Sarepta Therapeutics, Inc., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, University of Maryland, The Progeria Research Foundation
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • Methods of treating age-related symptoms in mammals and compositions therefor
    Patent number: 10603325
    Abstract: A method of alleviating age-related symptoms in a mammal, which comprises a step of administering to a mammal in need thereof, an effective amount of a composition containing an effective amount of at least methylene blue.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: March 31, 2020
    Assignee: UNIVERSITY OF MARYLAND
    Inventor: Kan Cao
  • Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
    Patent number: 10398721
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: September 3, 2019
    Assignees: SAREPTA THERAPEUTICS, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF MARYLAND, PROGERIA RESEARCH FOUNDATION, INC.
    Inventors: Ryszard Kole, Francis S. Collins, Michael R. Erdos, Kan Cao, Leslie B. Gordon
  • OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA
    Publication number: 20190127735
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 2, 2019
    Applicants: Sarepta Therapeutics, Inc., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF MARYLAND
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA
    Publication number: 20180271893
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Application
    Filed: October 6, 2017
    Publication date: September 27, 2018
    Inventors: RYSZARD KOLE, Francis S. Collins, Michael R. Erdos, Kan Cao
  • Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
    Patent number: 9833468
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: December 5, 2017
    Assignees: Sarepta Therapeutics, Inc., The United States of America, as represneted by the Secretary, Dept. of Health and Human Services, University of Maryland
    Inventors: Ryszard Kole, Francis S. Collins, Michael R. Erdos, Kan Cao
  • Methods of Treating Age-Related Symptoms in Mammals and Compositions therefor
    Publication number: 20170246177
    Abstract: A method of alleviating age-related symptoms in a mammal, which comprises a step of administering to a mammal in need thereof, an effective amount of a composition containing an effective amount of at least methylene blue.
    Type: Application
    Filed: October 27, 2015
    Publication date: August 31, 2017
    Applicant: UNIVERSITY OF MARYLAND
    Inventor: Kan CAO
  • METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA
    Publication number: 20170051278
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Application
    Filed: March 29, 2016
    Publication date: February 23, 2017
    Inventors: Ryszard Kole, Francis S. Collins, Michael R. Erdos, Kan Cao
  • Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
    Patent number: 9326992
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: May 3, 2016
    Assignees: Sarepta Therapeutics, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland
    Inventors: Ryszard Kole, Francis S. Collins, Michael R. Erdos, Kan Cao